ALNY : Analysis & Opinions

  1. Alnylam Expects Better 2017 After Setbacks

    January 12, 2017
    After weathering setbacks, Alnylam is more positive about the future prospects for its drug programs.
  2. Alnylam Hemophilia Drug Does Well In Study (ALNY)

    December 6, 2016
    Alnylam's hemophilia drug fitusiran was shown safe and effective in mid-stage clinical trials.
  3. Alnylam Tanks By Half (ALNY)

    October 6, 2016
    Suspension of key revusiran trials adds to the company’s woes. Alnylam halted ALN-AAT drug trials last week.
  4. Alnylam’s Drug Halt Tanks Stock by 9% (ALNY)

    October 1, 2016
    Though Alnylam announced a new drug development program as a replacement, it will be a long road to success.
  5. Top 10 Biotech Stocks for 2016 (ALXN, ALNY)

    August 30, 2016
    The biotechnology sector has many growth opportunities for the remainder of 2016. Here are the top ten biotech stocks, with ...
  6. The Top 5 Mid-Cap Biotechnology Stocks for 2016 (ALNY, ICPT)

    January 5, 2016
    Discover the top five mid-cap biotechnology stocks for 2016, with a brief summary, growth outlook and expected price target ...
  7. 8 Stages Of New Drug Development

    July 29, 2013
    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these ...
  8. Good IPO, Bad IPO

    June 17, 2009
    A good IPO will consider the needs of long-time investors as well as new ones. Here is the good the bad about two IPOs.